Skip to main content

Access to Medicines

CSL’s long-standing partnerships with patient groups and non-government organisations help to improve access to our therapies in developing countries (see following). In addition, CSL is active in supporting patient advocacy efforts for access to care globally.
Muslim woman with child

Bleeding Disorders

For more than 10 years, CSL Behring has supported the World Federation of Hemophilia (WFH) improve the diagnosis and treatment of bleeding disorders around the world.

In addition to its financial support for the organisation’s work, CSL Behring is a program sponsor and donor to the WFH’s Global Alliance for Progress (GAP) Program, a worldwide initiative seeking to save and improve the quality of life of people with bleeding disorders.

In 2017, CSL Behring donated more than 15 million international units of coagulation factor to the WFH, supporting patients in Afghanistan, Bangladesh, Belize, Cambodia, Cameroon, Côte d’Ivoire, Dominican Republic, El Salvador, Ethiopia, Ghana, Honduras, India, Jamaica, Lithuania, Madagascar, Malawi, Mali, Mauritania, Morocco, Niger, Nigeria, Philippines, Rwanda, Togo and Zambia.

Boy with bandage on arm


In 2017, Seqirus continued its support for the World Health Organization’s Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines (PIP Framework) with a corporate contribution. The PIP framework is an international arrangement adopted by the World Health Assembly in May 2011 to improve global pandemic influenza preparedness and response. It aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to pandemic influenza (e.g., vaccines, antiviral medicines and diagnostic products).

Seqirus has also agreed to donate 10% of influenza vaccine output in real time to WHO for deployment to developing countries in the event of a global pandemic emergency.

Picture of children drawing with color pencils

Primary Immunodeficiency

The Jeffrey Modell Foundation is devoted to early and precise diagnosis, meaningful treatments and, ultimately, cures for those with primary immunodeficiency (PI). CSL Behring has been a partner to this organization and its important work of creating PI diagnostic and research centers since its inception over 30 years ago.

In March 2017, the foundation announced its plans to open its first PI network and center in Africa, with CSL Behring a proud sponsor. The North African Network will join over 200 similar sites in the Jeffrey Modell Centers Network around the world. These centers offer advanced diagnostic evaluations to patients with suspected primary immune deficiencies and our support helps CSL to deliver on our promise to PI patients. In Africa, it’s estimated that the diagnosis rate of PI, a life threatening condition, is only about 0.3 percent.

Logo for the Papua New Ginea Snakebite Partnership


In April 2018, a new multi-stakeholder partnership was launched in Papua New Guinea (PNG), the “PNG Snakebite Project”, to help save lives from snakebite. PNG has some of the highest rates of snakebite mortality in the world, caused mainly by taipan and death adder envenomation. The same snake species are found in Australia, where Seqirus antivenom has been in use for decades.

The partnership, a three-year project involving the PNG National Department of Health, the Australian High Commission, Seqirus and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea, is intended to significantly improve access to antivenoms by combining a large product donation, healthcare worker training, plus a purpose-built cold-chain distribution and product management system.

Under the partnership, Seqirus will provide an annual donation of 600 vials of snake and marine creature antivenoms to PNG valued at more than A$1 million annually.